What are good, affordable add-on options to metformin (biguanide) for patients with impaired glucose regulation?

Affordable Add-On Options to Metformin for Impaired Glucose Regulation

For patients with impaired glucose regulation who need additional therapy beyond metformin, sulfonylureas (particularly glimepiride) are the most affordable and effective add-on option, followed by SGLT2 inhibitors or GLP-1 receptor agonists if cardiovascular or renal benefits are needed. 1

Cost Comparison of Add-On Options

Based on the most recent guidelines, here's a cost comparison of common add-on options to metformin:

Most Affordable Options:

• Sulfonylureas: $4-17 per month (median AWP)

  • Glimepiride (4 mg): $74 ($4 NADAC)
  • Glipizide (10 mg): $75 ($5 NADAC)
  • Glyburide (5 mg): $93 ($11 NADAC)

• Thiazolidinediones:

  • Pioglitazone (45 mg): $348 ($4 NADAC)

Moderate Cost Options:

• SGLT2 inhibitors: $271-475 per month (NADAC)

  • Ertugliflozin (15 mg): $338 ($271 NADAC)
  • Empagliflozin (25 mg): $591 ($473 NADAC)
  • Dapagliflozin (10 mg): $591 ($473 NADAC)

• DPP-4 inhibitors: $168-433 per month (NADAC)

  • Alogliptin (25 mg): $234 ($168 NADAC)
  • Sitagliptin (100 mg): $541 ($433 NADAC)

Most Expensive Options:

• GLP-1 receptor agonists: $600-886 per month (NADAC)
  • Exenatide extended-release (2 mg): $840 ($672 NADAC)
  • Dulaglutide (1.5 mg): $911 ($730 NADAC)
  • Semaglutide (1 mg): $927 ($745 NADAC)

1

Decision Algorithm for Selecting Add-On Therapy

1. If cost is the primary concern AND no cardiovascular/renal disease:

   • Choose sulfonylureas (glimepiride preferred due to lower hypoglycemia risk)

2. If patient has established ASCVD, heart failure, or CKD:

   • Choose SGLT2 inhibitor (most affordable: ertugliflozin)
   • Alternative: GLP-1 receptor agonist (if SGLT2 inhibitor contraindicated)

3. If hypoglycemia is a major concern:

   • Choose DPP-4 inhibitor (most affordable: alogliptin)
   • Alternative: SGLT2 inhibitor

4. If weight management is important:

   • Choose SGLT2 inhibitor or GLP-1 receptor agonist (causes weight loss)
   • Avoid sulfonylureas (cause weight gain)

1, 2

Efficacy Comparison

• Sulfonylureas: 1.0-1.5% A1C reduction 2
• SGLT2 inhibitors: 0.7-1.0% A1C reduction 2
• DPP-4 inhibitors: 0.5-0.7% A1C reduction 2
• GLP-1 receptor agonists: 0.8-1.5% A1C reduction 2
• Thiazolidinediones: 0.7-1.0% A1C reduction 2

Evidence for Specific Add-On Options

Sulfonylureas (Most Affordable)

• Glimepiride showed similar efficacy to empagliflozin in reducing HbA1c (-0.36% vs -0.16%) when added to metformin 3
• However, glimepiride had significantly higher rates of hypoglycemia (36% vs 7%) and weight gain (+1.2 kg vs -0.8 kg) compared to sitagliptin 4

SGLT2 Inhibitors (Moderate Cost with CV Benefits)

• Empagliflozin demonstrated non-inferiority and even superiority to glimepiride for glycemic control after 104 weeks (-0.11% difference) 3
• Significantly fewer hypoglycemic events (2% vs 24%) and cardiovascular events (12 vs 26 patients) compared to glimepiride 3
• Provides additional benefits of weight reduction and blood pressure lowering 2

DPP-4 Inhibitors (Moderate Cost with Neutral Weight Effect)

• Sitagliptin showed non-inferiority to glimepiride in HbA1c reduction (-0.47% vs -0.54%) 4
• Significantly fewer hypoglycemic events (7% vs 22%) and weight benefit (-0.8 kg vs +1.2 kg) compared to glimepiride 4

Important Considerations and Caveats

1. Hypoglycemia risk: Sulfonylureas carry a significantly higher risk of hypoglycemia compared to other options. This is particularly important for elderly patients or those with irregular meal schedules 1, 4

2. Weight effects:

   • Weight gain: Sulfonylureas (+1-3 kg)
   • Weight neutral: DPP-4 inhibitors
   • Weight loss: SGLT2 inhibitors (-1.5 to -3.5 kg), GLP-1 RAs (-1 to -4 kg) 2

3. Renal function:

   • SGLT2 inhibitors have decreased efficacy when eGFR <45 mL/min/1.73m² and are not recommended for eGFR <30 2
   • DPP-4 inhibitors generally require dose adjustment with reduced renal function 2
   • Sulfonylureas may increase hypoglycemia risk in renal impairment 1

4. Cardiovascular benefits:

   • SGLT2 inhibitors and GLP-1 RAs have demonstrated cardiovascular benefits 1, 2
   • Sulfonylureas and DPP-4 inhibitors are generally neutral for cardiovascular outcomes 2

5. Common pitfall: Delaying treatment intensification when needed. Guidelines recommend evaluating therapy effectiveness every 3-6 months and adjusting as needed 1

For most patients requiring add-on therapy to metformin with cost as a primary concern, sulfonylureas (particularly glimepiride) represent the most affordable option with good efficacy, though they come with increased hypoglycemia and weight gain risks. If cardiovascular or renal protection is needed, SGLT2 inhibitors offer the best balance of moderate cost and proven benefits.